Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2020

View Archived Issues

Phase I study of hCT-MSC in neonates with hypoxic-ischemic encephalopathy

Design and characterization of novel topoisomerase II poisons with improved drug-like profile

New D peptide blocking TIGIT/PVR binding for cancer immunotherapy even in anti-PD-1-resistant tumors

Elixirgen advances COVID-19 vaccine candidate EXG-5003 following pre-IND meeting with FDA

Phase II data for tomivosertib added to continued checkpoint inhibitor therapy

Bermekimab + nanoliposomal irinotecan and 5-FU/FA shows efficacy in refractory pancreatic cancer

Antiviral vaccine protects against myocarditis, diabetes

First healthy volunteer dosed in phase I trial of ARCT-810

FDA clears IND application for BX-U001 in rheumatoid arthritis

TQ-B3525 demonstrates safety and promising antitumor activity in phase I trial

Series B financing extension to support Artax's development of AX-158 for autoimmune diseases

Phase I data presented for anti-EGFR ADC MRG-003 in relapsed/refractory solid tumors

Survival improved with apatinib in Chinese patients with pretreated hepatocellular carcinoma

BeiGene patents new MAP4K1 inhibitors

TES Pharma describes ACMSD inhibitors

Qilu Regor Therapeutics identifies GLP-1 receptor agonists

Inception IBD discloses new VNN1 inhibitors

Sleep deprivation kills through punch to the gut

New arginase inhibitors presented by Arcus Biosciences

SARS-CoV-2 neutralizing antibody JS-016 begins phase I study in China

Bavarian Nordic reports first-in-human data on equine encephalitis virus vaccine MVA-BN WEV

Lumosa initiates phase I/II study of LT-5001 for uremic pruritus in hemodialysis patients

Enrollment underway in phase III trial of MBG-453 for MDS and CMML-2

Mabspace begins first-in-human study of TST-001 in advanced or metastatic solid tumors

FibroGen announces new trials of pamrevlumab for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...